Comparing Cost-Effectiveness of First-Line Treatment Approaches for Hodgkin Lymphoma
Of 5 treatment regimens assessed, a PET-adapted de-escalation treatment approach was found to be the most cost-effective in 87% of cases modelled.
Hodgkin Lymphoma
The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma
[Blood and Lymphatic Cancer: Targets and Therapy] First approved in 2011, the CD30 directed antibody-drug conjugate brentuximab vedotin is used in previously untreated and R/R classical Hodgkin lymphoma (cHL). In this review, researchers discuss the expanded indications for BV in cHL to include maintenance therapy after ASCT and in combination with chemotherapy and immunotherapy.
Survival Worse for Nonwhite Children With Hodgkin Lymphoma
Risk for postrelapse mortality 2.7-, 3.5-fold higher for Hispanics, non-Hispanic blacks versus whites.
Treatment Strategies for Lymphoma in Patients With HIV
Cancer, particularly non-Hodgkin lymphoma, remains a leading cause of death in patients with HIV who are being treated with antiretroviral therapy.
Pretreatment Vitamin D Deficiency Associated With Outcomes in Hodgkin Lymphoma
Patients with Hodgkin lymphoma who were deficient for vitamin D experienced reduced progression-free and overall survival.
Weighing Benefits, Risks of Antenatal Chemotherapy in Pregnant Women With Hodgkin Lymphoma
A retrospective cohort study explored outcomes for pregnant women with HL who received antenatal chemotherapy compared with a match cohort of nonpregnant women.
Differences in Postrelapse Mortality May be Driving Racial/Ethnic Disparities Observed in Children With Hodgkin Lymphoma
No difference in event-free survival (EFS) was observed in children and adolescents with newly diagnosed Hodgkin lymphoma (HL) according to race/ethnicity; however, postrelapse mortality was found to be higher in nonwhite groups. The findings from this pooled, secondary analysis of data from phase 3 clinical trials of dose-dense, response-adapted therapy were published in the Journal…
Hodgkin Lymphoma Diagnosis During Pregnancy Does Not Appear to Affect Maternal Survival
In an assessment of data from the International Network on Cancer registry, researchers determined that maternal 5-year survival for pregnant women with HL was comparable to that of their nonpregnant counterparts.
Trial to Assess Brentuximab Vedotin With Adriamycin, Vinblastine, and Dacarbazine in Pediatric Patients With Hodgkin Lymphoma
The purpose of this study is to assess the safety, tolerability, and antitumor activity, as well as recommended dose of brentuximab vedotin in combination with a multiagent chemotherapy regimen.
Number of Comorbidities Linked to Risk of Thromboembolism in Leukemia, Lymphoma
A retrospective study sought to determine the risk factors for thromboembolism in patients with acute leukemia or lymphoma.
Next post in Leukemia
